肝CT灌注成像技术在肝脏肿瘤应用现状、存在的问题及展望  

Liver CT Perfusion Imaging in Liver Tumor Application Status,Problems and Prospects

作　　者：赵旭[1] 纪凤颖[1] 常燃[1] 赵雪珂[1] 刘丰 周阳[1] ZHAO Xu,JI Feng-ying,CHANG Ran,ZHAO Xue-ke,LIU Feng,ZHOU Yang(Department of Radiology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, 150001, Chin)

机构地区：[1]哈尔滨医科大学附属第一医院CT室,黑龙江哈尔滨150001

出　　处：《现代生物医学进展》2018年第4期797-800,700,共5页Progress in Modern Biomedicine

基　　金：黑龙江省自然科学基金项目(D201232)

摘　　要：CT灌注成像(CT perfusion imaging,CTPI)作为一种功能成像技术可无创性评估靶目标的血流动力学情况。自1993年Mile等首次报道其在肝脏肿瘤的应用以来,随着工业技术的进步,软硬件的更新,既往CTPI存在的问题,诸如,辐射剂量过高,扫描协议缺乏标准化,呼吸运动伪影,结果可重复性问题,扫描范围较小等问题均得到了不同程度的改善,使其在肝脏肿瘤应用中表现出了巨大的潜力。众所周知,CTPI的出现弥补了传统形态学成像方式对肿瘤的早期诊断,预后评估,检测新型分子靶向药物疗效等的不足。本文总结了近年来肝CTPI技术在肝肿瘤应用现状、存在的问题及未来展望。As a functional imaging technique, CT perfusion imaging（CTPI） can realize the noninvasive evaluation of the target＇s blood flow dynamics. Since its first reported application on liver tumors by Mile in 1993, with technological development and hardware/software updates, previous CTPI problems（such as high radiation doses, lacking of standardized scanning protocol, respiratory motion artifact, reproducible results, limited scanning range, etc.） have been solved to a certain extent, showing a great potential in its application on the treatment of liver tumors. It is well known that CTPI makes up for the deficiency of traditional morphological imaging in early diagnosis of tumors, prognosis assessment, and efficacy detection of new molecularly targeted chemotherapeutics. This paper summarized the current status, existing problems and prospects of CTPI＇s application on liver tumor in recent years.

关 键 词：CT灌注成像 肝脏 肿瘤学 

分 类 号：R735.7[医药卫生—肿瘤] R814.42[医药卫生—临床医学]